Hemab Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Hemab Therapeutics's estimated annual revenue is currently $7.9M per year.
- Hemab Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Hemab Therapeutics has 51 Employees.
- Hemab Therapeutics grew their employee count by 96% last year.
Hemab Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Medical Affairs and Global External Engagement | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
Hemab Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Hemab Therapeutics?
Hemab ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
keywords:N/AN/A
Total Funding
51
Number of Employees
$7.9M
Revenue (est)
96%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Hemab Therapeutics News
Maraganore serves as the chair of Hemab Therapeutics and as a director of Agios Pharmaceuticals, Beam Therapeutics, and Kymera Therapeutics. He...
He has taken board positions at Hemab Therapeutics, Kymera Therapeutics and Rain Therapeutics. Maraganore has also been tapped to serve as a...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10.5M | 52 | 37% | N/A |
#2 | $6.3M | 54 | -30% | N/A |
#3 | $7M | 54 | -5% | N/A |
#4 | N/A | 54 | 2% | N/A |
#5 | $14.1M | 54 | 93% | N/A |